TransMedics Group (NASDAQ:TMDX – Get Free Report) and DarioHealth (NASDAQ:DRIO – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Volatility and Risk
TransMedics Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for TransMedics Group and DarioHealth, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TransMedics Group | 0 | 6 | 6 | 0 | 2.50 |
| DarioHealth | 1 | 1 | 1 | 0 | 2.00 |
Earnings & Valuation
This table compares TransMedics Group and DarioHealth”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TransMedics Group | $605.49 million | 3.93 | $190.29 million | $4.40 | 15.65 |
| DarioHealth | $22.36 million | 2.51 | -$41.71 million | ($8.88) | -0.87 |
TransMedics Group has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 3.5% of DarioHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares TransMedics Group and DarioHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransMedics Group | 27.04% | 22.38% | 8.46% |
| DarioHealth | -192.23% | -60.52% | -37.08% |
Summary
TransMedics Group beats DarioHealth on 14 of the 14 factors compared between the two stocks.
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
About DarioHealth
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
